Position in ADCT
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$58,523
-$15,215 QoQ
Shares Held
54,695
+161.8% QoQ
Ownership
0.043%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#52
of 113 holders
Holding Since
Mar 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $11,914,926 across 21 Drug Manufacturers - Specialty & Generic names. ADCT ranks #19 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INDV |
Indivior Pharmaceuticals, Inc.
|
55,201 | $2,264,897 | |
| 2 | ZTS |
Zoetis Inc.
|
18,470 | $1,327,254 | |
| 3 | IRWD |
Ironwood Pharmaceuticals Inc
|
259,512 | $1,092,545 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
90,210 | $902,100 | |
| 5 | LQDA |
Liquidia Corp
|
10,098 | $805,113 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
11,219 | $717,455 | |
| 7 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
39,241 | $704,768 | |
| 8 | XERS |
Xeris Biopharma Holdings, Inc.
|
82,830 | $656,013 |
All Filings in ADCT
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $58,523 | 54,695 | Shares | Sole | 2026-08-06 | |
| 2025-12-31 | $73,738 | 20,889 | Shares | Sole | 2026-02-06 | |
| 2023-09-30 | $109,341 | 121,897 | Shares | Sole | 2023-11-15 | |
| 2023-06-30 | $234,102 | 108,885 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $46,113 | 23,648 | Shares | Sole | 2023-05-12 | |
| No filing history on record for this holder in this stock. | ||||||